A couple of years ago Wyeth introduced a new R&D protocol in drug development. It was named “Learn & Confirm” and relies most heavily on biomarkers and pharmacogenomic approaches.
As part of Learn and Confirm, Wyeth drug-development teams were encouraged to examine each compound coming through the pipeline for ways that the company can employ a biomarker-based or pharmacogenomic approach that can help move it downstream.
This R&D Methodology was based on the research developed by Lewis B. Sheiner synthesized in the paper “Clinical Pharmacology and Therapeutics” .
This methodology is naturally consistent with the unicist complexity research methodology. Therefore we working with CROs to expand this technology using the unicist healthcare cybernetic approach synthesized in the Unicist Cyberstation.